2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Brain Ischemia D002545 89 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Epilepsy D004827 35 associated lipids
Nerve Degeneration D009410 53 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Morphine Dependence D009021 9 associated lipids
Catalepsy D002375 30 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Hypothermia D007035 19 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Brain Concussion D001924 5 associated lipids
Encephalitis D004660 15 associated lipids
Memory Disorders D008569 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neuralgia D009437 28 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Acute Pain D059787 3 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
van der Stelt M et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. 2005 FASEB J. pmid:15894565
Lambert DM and Fowler CJ The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. 2005 J. Med. Chem. pmid:16078824
Hayase T et al. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. 2005 Behav Pharmacol pmid:16148444
Venderova K et al. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. 2005 Exp. Neurol. pmid:15899265
Gokoh M et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. 2005 Biochem. J. pmid:15456404
Sancho R et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. 2005 J. Immunol. pmid:16148147
Harada N et al. Effects of cannabinoids on colonic muscle contractility and tension in guinea pigs. 2005 J Nippon Med Sch pmid:15834207
Hill MN et al. Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. 2005 Eur. J. Pharmacol. pmid:16324692
Gokoh M et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. 2005 FEBS Lett. pmid:16288744
Iturralde M et al. Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. 2005 Apoptosis pmid:16215685
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Alger BE Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. 2005 Sci. STKE pmid:16278487
Rademacher DJ et al. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). 2005 Neurotoxicology pmid:15527869
Shoemaker JL et al. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. 2005 J. Pharmacol. Exp. Ther. pmid:16081674
Jung KM et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. 2005 Mol. Pharmacol. pmid:16051747
Makara JK et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. 2005 Nat. Neurosci. pmid:16116451
Ligresti A et al. Endocannabinoid metabolic pathways and enzymes. 2005 Curr Drug Targets CNS Neurol Disord pmid:16375679
Secko D Analgesia through endogenous cannabinoids. 2005 CMAJ pmid:16103504
Maejima T et al. Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. 2005 J. Neurosci. pmid:16033892
Panikashvili D et al. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. 2005 J. Cereb. Blood Flow Metab. pmid:15729296
Gopez JJ et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. 2005 Neurosurgery pmid:15730585
Zhao Q et al. 2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells. 2005 J. Biol. Chem. pmid:15886210
Rouzer CA and Marnett LJ Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. 2005 J. Biol. Chem. pmid:15917246
Nithipatikom K et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. 2005 Biochem. Biophys. Res. Commun. pmid:15919052
Darmani NA et al. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. 2005 Neuropharmacology pmid:15921709
Kola B et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. 2005 J. Biol. Chem. pmid:15899896
Gauthier KM et al. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:15528233
Gabbay E et al. Endocannabinoids and liver disease--review. 2005 Liver Int. pmid:16162147
Vandevoorde S et al. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. 2005 Biochem. Biophys. Res. Commun. pmid:16181610
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
Ramos JA et al. Therapeutic potential of the endocannabinoid system in the brain. 2005 Mini Rev Med Chem pmid:16026307
Wagner JA et al. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. 2005 J. Cardiovasc. Pharmacol. pmid:16116341
McPartland JM et al. Cannabimimetic effects of osteopathic manipulative treatment. 2005 J Am Osteopath Assoc pmid:16118355
Wahn H et al. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:16055511
Kurabayashi M et al. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. 2005 Jan-Feb J Invest Surg pmid:15804949
Quistad GB et al. Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. 2006 Toxicol. Appl. Pharmacol. pmid:16310817
Panikashvili D et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. 2006 Neurobiol. Dis. pmid:16364651
Parkkari T et al. Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE). 2006 Bioorg. Med. Chem. pmid:16403642
Suplita RL et al. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. 2006 Neuropharmacology pmid:16316669
Saario SM et al. URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. 2006 Chem. Biol. pmid:16931330
Sang N et al. PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. 2006 J. Physiol. (Lond.) pmid:16484297
Parkkari T et al. Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability. 2006 Bioorg. Med. Chem. Lett. pmid:16466915
Kurihara R et al. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. 2006 J. Biol. Chem. pmid:16513651
Mestre L et al. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. 2006 Biochem. Pharmacol. pmid:16914119
Blüher M et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. 2006 Diabetes pmid:17065342
Oka S et al. Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. 2006 J. Immunol. pmid:17142782
Oka S et al. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. 2006 Eur. J. Pharmacol. pmid:16647054
Melis M et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. 2006 Neurobiol. Dis. pmid:16762556
Malcher-Lopes R et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. 2006 J. Neurosci. pmid:16775153
Kishimoto S et al. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. 2006 Int. Arch. Allergy Immunol. pmid:16772720